Azenta, Inc. (AZTA)

NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-23

$36.50+1.36%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Azenta, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
EBITDA	$20M–$23Mnon-GAAP	—
FY 2027 · Q1
Revenue	—	154.3M
EPS	—	0.067
FY 2026 · Annual
Revenue	$603M–$621M	—
FY 2027 · Annual
Revenue	—	639.25M
EPS	—	0.478
FY 2028 · Annual
Revenue	—	670.22M
EPS	—	0.695

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Free cash flow margin	Free cash flow is expected near 12% next quarter.	Intact	FCF margin falls below 10% next quarter	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Multiomics revenue growth	A primary condition in Azenta, Inc.'s published investment case. The stated target is >=4% YoY revenue growth.	Improving	YoY revenue growth falls below 0% next year	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Multiomics revenue showed mixed performance: $67M in 2026-Q1 (+1% YoY), $64M in 2026-Q2 (flat YoY), and $73M in 2026-Q3 (+10% YoY). Management emphasizes transformation with focus on commercial execution and productivity. The trajectory shows mixed progress with recent improvement in 2026-Q3, consistent with management's ongoing focus. Delivery assessment Oct 24, 2026
Total company revenue growth	A supporting condition in Azenta, Inc.'s published investment case. The stated target is >=4% YoY revenue growth.	Improving	YoY revenue growth falls below 3% next year	Revenue growth: 11.97% FY2026-Q3; GAAP. Published target: >=4% YoY revenue growth. Target period is not explicitly aligned with this observation. Source published Aug 6, 202611.974267 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: e94a3cf5-c6ac-4056-bf35-0b2e43a9b5a4. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-09-30 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-10-01	Unavailable	Unavailable	1 / 3
2026-10-02	Unavailable	Unavailable	1 / 3
2026-10-03	Unavailable	Unavailable	1 / 3
2026-10-04	Unavailable	Unavailable	1 / 3
2026-10-05	Unavailable	Unavailable	1 / 3
2026-10-06	Unavailable	Unavailable	1 / 3
2026-10-07	Unavailable	Unavailable	1 / 3
2026-10-08	Unavailable	Unavailable	1 / 3
2026-10-09	Unavailable	Unavailable	1 / 3
2026-10-10	Unavailable	Unavailable	1 / 3
2026-10-11	Unavailable	Unavailable	1 / 3
2026-10-12	Unavailable	Unavailable	1 / 3
2026-10-13	Unavailable	Unavailable	1 / 3
2026-10-14	Unavailable	Unavailable	1 / 3
2026-10-15	Unavailable	Unavailable	1 / 3
2026-10-16	Unavailable	Unavailable	1 / 3
2026-10-17	Unavailable	Unavailable	1 / 3
2026-10-18	Unavailable	Unavailable	1 / 3
2026-10-19	Unavailable	Unavailable	1 / 3
2026-10-20	Unavailable	Unavailable	1 / 3
2026-10-21	Unavailable	Unavailable	1 / 3
2026-10-22	Unavailable	Unavailable	1 / 3
2026-10-23	Unavailable	Unavailable	1 / 3
2026-10-24	Unavailable	Unavailable	2 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	3	3
2026-06-01	3	3
2026-07-01	3	3
2026-08-01	3	3
2026-09-01	3	3
2026-10-01	3	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Free cash flow marginDirect metric needs a verified mapping
Multiomics revenue growthDirect metric needs a verified mapping
Total company revenue growthRevenue growth: 11.97%

Next proof point

Nov 20, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.8%Typical daily move · historical

Downside history

-60.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Azenta, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a challenged growth business with a transformation underway, rather than a proven compounder. The 1-to-3-year thesis is on watch: Multiomics has improved recently, but overall financial performance remains weak and earnings have been loss-making.

What's priced into Azenta, Inc.

AZTA is described as cheap versus peers, while the model confidence is low and the expectations gap is modest. The evidence does not show that the weak results and elevated risks are fully reflected in the valuation, so the peer discount alone does not settle the thesis.

What the fundamentals likely do

Near term, organic growth looks limited: fiscal 2026 guidance was cut from 3%-5% growth to flat to up 1%, although Sample Management Solutions grew 14% in the third quarter. Multiomics revenue was mixed across recent quarters, with a 10% year-over-year increase in the latest quarter, while the B Medical Systems sale is complete. Recent results have been weak and earnings surprises erratic, so the next guidance update remains a risk.

What Azenta, Inc. hinges on

The multi-year view hinges on whether management can sustain Multiomics improvement and turn its commercial execution and productivity efforts into stronger organic growth. A guidance cut or further labor-market weakness would add pressure; continued strong results and higher guidance from healthcare peers could support the sector backdrop.

Bottom line

Over the next 1 to 3 years, the central question is whether AZTA’s transformation can deliver more consistent growth and better results despite near-term execution and economic risks. The valuation is cheap versus peers, but the evidence remains mixed and model confidence is low. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.